News Related to A3 Adenosine Receptor Agonist

Related coverage linked through entity extraction aliases.

Cancer Pipeline Reports Show 45+ CSCC, 70+ Liver Cancer, and Multiple HCC Therapies in Development

Mar 20, 2026

DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.

Can-Fite's Namodenoson Shows Promise in Pancreatic Cancer and Obesity Studies

Mar 04, 2026

Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.